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OBJECTIVES: The aim of this study was to investigate the impact of chronic auto-
immune diseases, mainly rheumatoid arthritis (RA), on functional status among 
patients in Slovakia. METHODS: Patients were prospectively recruited in the 
National Institute for Rheumatic Diseases in Slovakia during 2014 and data from 
patients on disease impact on their life were collected from physicians through a 
specifically designed questionnaire. Functional status and disability assessments 
were conducted among patients with RA using the Stanford Health Assessment 
Questionnaire (HAQ). RESULTS: The sample (100 respondents) was predominantly 
female (82%) with diagnosis of RA (86%). The average age was 51 with 14-year dura-
tion of the disease average. Thirty-eight percent of patients had osteoporosis, 21% 
a cardiovascular disease and 29% patients underwent surgery due to autoimmune 
diseases – 3 times on average. The most common symptom, occurring more than 
once a week, was fatigue. Patients reported also reduced physical activity, pain 
and specifically joint pain. Manifestations of the disease were on average at a mild 
intensity. Full work disability was more common (37%) than partial work disability 
(29%) in the sample. HAQ final score ranged from 0 (no disability) to 3 (severe dis-
ability) with average HAQ score 1.35 (SD= 0.59). Majority of patients reported some 
or much difficulty in all HAQ domains and the highest disability was found for the 
domains of reach (score 1.59) and grip (1.54). HAQ score is increasing with the dis-
ease duration: average HAQ score in patients with RA lasting less than 10 years was 
significantly lower (1.17) than in patients with the disease duration of 20 years and 
more (1.61). CONCLUSIONS: Results indicate that chronic autoimmune diseases, 
mainly rheumatoid arthritis (RA), have negative impact on activities of daily living 
and the most commonly reported symptoms are fatigue and pain. Functional status 
is worsening with the duration of the disease.
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OBJECTIVES: The aim of this study was to investigate the socio-economic impact of 
chronic autoimmune diseases, mainly rheumatoid arthritis (RA) and work disabili-
ties, among patients in Slovakia. METHODS: Patients were prospectively recruited 
in the National Institute for Rheumatic Diseases in Slovakia during the year 2014 
and the data from patients on disease impact on their life were collected by con-
sulting physicians through a specifically designed questionnaire. RESULTS: The 
sample (100 respondents) was predominantly female (82%) with diagnosis of RA 
(86%). As many as 66% of the patients became permanently work disabled at the 
average age of 42 years, with full work disability being more common (37%) than 
partial work disability (29%). The occurrence of sick leave in the past 12 months 
among patients with a job was 48% with an average length of 30 days. Twenty-
three percent of respondents had to change their jobs due to the disease. Average 
personal expenses connected with the treatment in the last 3 months were 74 € , 
out of that the highest were their costs of traveling. 74% of respondents stated 
restrictive (52%) or very restrictive (22%) impact of the disease on their function-
ing, mostly in strenuous activities or sport. Three most frequently reported areas 
negatively affected by the disease were: social activities (reported by 63% respond-
ers), professional career (49%) and quality of a relationship with their partner (28%). 
Areas that have improved in comparison with the period when patients started 
their treatment were: communication with healthcare personnel and more effec-
tive therapies available. The support from patient organizations wasn’t perceived 
as significant. CONCLUSIONS: The occurrence of permanent work disability and 
sick leave was substantial in the sample. This study in patients with autoimmune 
chronic conditions - mainly RA, showed significant impact of the disease on work 
capabilities and socio-economic status.
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OBJECTIVES: Using an example of a new drug for rheumatoid arthritis which 
offers comparable effectiveness and side-effect point estimates to older drugs, we 
explore preferences for treatments labelled ‘new’. We then examine the persistence 
of preferences once ambiguity in the evidence base due to it being new is intro-
duced. METHODS: A representative Canadian population sample (n= 2837) was ran-
domized to one of three discrete choice experiment (DCE) designs, seeking choices 
between hypothetical treatments for rheumatoid arthritis with different levels of 
7 attributes: route and frequency of administration, chance of benefit, serious and 
minor side-effects, life expectancy, and uncertainty in benefit and side-effect esti-
mates. DCEs differed in whether the treatment was 1) described as new (recently 
available) or older (5 or 10 years), 2) whether a qualitative description describing 
the confidence in the evidence was included instead, or 3) both the length of time 
available and confidence in evidence was provided. We collected self-reports of 
respondent innovativeness, numeracy, and risk attitude. RESULTS: Overall, all 6 
consistent attributes influenced preferences for treatment. A preference for less 
ambiguity (more confidence) in benefit and side-effect estimates was observed, but 
no preference for a treatment labelled ‘new’ or ‘old’. Early adopters (n= 173) had a 
significant preference for ‘newer’ treatments relative to old treatments (B= 0.157, 
p= 0.045). The magnitude of preference for new treatments was comparable with 
preferences for reducing the risks of serious side-effects in this group. When the 
newness of the drug was combined with ambiguity in the evidence base, these 
preferences for ‘new’ treatments diminished. CONCLUSIONS: Preferences for inno-
vation in health care exist for some groups of people, but when presented with the 
implications of new treatments (increased ambiguity in evidence), these prefer-
ences diminished. Physicians should either avoid describing whether treatments 
are ‘new’, or qualify the implications of a ‘new’ treatment in terms of ambiguity in 
estimates of risks and benefits.
ried (77.9%), had college/graduate degrees (59.5%), and had income > $75,000 (58.7%). 
The mean HAQ scores was 0.48+0.55 with 79.2% (n= 137) having HAQ < 1, 18.5% 
(n= 37) between 1-2, and 2.3% (n= 4) > 2. 60.3% (n= 105) employed patients reported 
high knowledge and high motivation while only 7.5% (n= 13) reported low knowl-
edge and low motivation on MMS. Most employed respondents (90.4%, n= 150) did 
not miss work due to RA with mean hours lost in the last seven days reported as 
1.04+5.18 (0-40hrs). 54.4% (n= 93) reported working more than 40 hours over the past 
seven days. Employed patients reported mean score of 1.8+2.2 for work impairment 
and 2.27+ 2.35 daily activities impairment due to their RA (measured on a scale of 
0-10 where 0 was no problem and 10 was major problem). CONCLUSIONS: Within 
the employed population, RA seems to have little effect on absenteeism, work pro-
ductivity and daily activities. High motivation and knowledge (adherence) and low 
disease severity maybe significantly and independently contributing to a favorable 
patient-perceived work productivity.
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OBJECTIVES: To evaluate the relationship between medication adherence, disease 
severity and employment status in patients with rheumatoid arthritis METHODS: 
A list of 3000 patients (18-65 years) were identified from a Specialty Pharmacy data-
base. 1,041 patients with a diagnosis of rheumatoid arthritis (RA) were identified 
from the list and were invited to participate in a survey. The patients were mailed 
a cover letter, consent letter, and a demographic questionnaire. Additionally, the 
Work Productivity and Activity Impairment (WPAI) questionnaire (assess produc-
tivity losses), Health Assessment Questionnaire (HAQ; disease severity), Modified 
Morisky Scale (MMS; medication adherence) were administered. Survey responses 
were linked to clinical measures obtained from the specialty pharmacy data-
base. Descriptive and logistic regression analyses were conducted using employ-
ment status as an outcome variable and HAQ, adherence, and demographics 
as input variables. The statistical analyses were conducted using SPSS version 
22.0. RESULTS: The response rate was 30.45% (n= 317). Based on WPAI results, 
57.4% (n= 174) identified themselves as being employed. Differences in mean age 
and mean HAQ scores of employed (54.09 years; 0.48) and unemployed (64.13 years; 
0.96) were statistically significant (p< 0.001) while there was no difference in the 
disease duration (p= 0.494). 47.3% of unemployed and 21.8% employed had HAQ 
scores greater than 1. There was a statistically significant difference in employed 
vs. unemployed (p< 0.001) across disease severity based on HAQ. While there was 
no difference in the level of knowledge (p= 0.187), there was a statistically signifi-
cant difference (p< 0.001) in the level of motivation between employed (63.5% high 
motivation) and unemployed (82% high motivation) respondents. CONCLUSIONS: 
Study results showed that employed patients, while having similar disease dura-
tion and level of knowledge, reported lower motivation on the MMS adherence 
scale. Although these patients had less severe RA compared to unemployed, this 
could act as a potential barrier to chronic treatment management and needs to 
be assessed in clinical practice.
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OBJECTIVES: The ultimate goals in managing Rheumatoid Arthritis (RA) are prevent-
ing or controlling joint damage, preventing loss of function and decreasing pain. 
Assessment of disease activity is critical; therefore, guidelines recommend that 
physicians evaluate patients’ symptoms and severity. The objective of this study was 
to examine how often evaluation of disease activity and damage in patients with RA 
was documented by physicians during office visits. METHODS: We extracted 300 
records for RA patients from a unique database of physician-patient interactions 
(RealHealthData). Using Atlas.ti, we analyzed these records to evaluate how often 
the recommended assessments of disease activity was documented by physicians 
during office visits. RESULTS: Almost all physicians (92%) document the presence 
of actively inflamed joints (i.e., tender and swollen joint counts) and evidence of dis-
ease progression (i.e., loss of motion, deformity). However, only 28% and 18% docu-
ment duration of morning stiffness and fatigue respectively. And while limitation 
of function is explored, only 11% documented the degree of joint pain via a visual 
analog scale. Lastly, it was rare for physicians to document their own global assess-
ment of disease activity (5%) or the patient’s global assessment of disease activity 
(8%). CONCLUSIONS: The more we know about patients’ reported symptoms and 
outcomes, the more we can actively plan and organize research, development and 
outreach that is patient-centric and clinically meaningful. Successful treatment 
includes systematic and regular evaluation of disease activity and patient assess-
ments to help limit joint damage and functional loss. While many physicians are 
documenting the number of tender and swollen joints, loss of motion or deformity, 
a majority of physicians are not documenting patient-reported symptoms that are 
critical to disease monitoring such as morning stiffness, fatigue or overall degree of 
joint pain. Our results demonstrate there is room for improvement when it comes 
to documenting patient-reported outcomes in RA.
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